Securities code: Jiangxi Sanxin Medtec Co.Ltd(300453) securities abbreviation: Jiangxi Sanxin Medtec Co.Ltd(300453) Announcement No.: 2022015 Jiangxi Sanxin Medtec Co.Ltd(300453)
Announcement on 2022 financing plan
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete without false records, misleading statements or major omissions.
Jiangxi Sanxin Medtec Co.Ltd(300453) (hereinafter referred to as “the company”) held the 17th meeting of the 4th board of directors and the 16th meeting of the 4th board of supervisors on March 15, 2022, deliberated and adopted the proposal on the company’s 2022 annual financing plan. The relevant information is hereby announced as follows:
1、 Overview of financing plan
According to the company’s strategic development plan, in order to ensure sufficient cash flow, meet the needs of the company’s expanding business scale and create more value for the company and shareholders, the company and its subsidiaries plan to apply for loans from banks and other financial institutions and other legal ways of debt financing in 2022, with a total amount of no more than 500 million yuan, The specific financing methods approved by the CSRC, including the amount of securities issued by the exchange and the amount of loans that can be used by the subsidiary, but not limited to the amount of loans approved by the CSRC.
In order to improve work efficiency and handle financing business in time, the board of directors is requested to authorize the chairman or vice chairman of the company to review and sign relevant agreements and documents on financing matters (except those that should be submitted to the general meeting of shareholders for deliberation in accordance with laws, regulations and the articles of association).
The total amount of the 2022 annual financing plan of the company and its subsidiaries approved by the board of directors is valid from the date of deliberation and approval by the board of directors to the date of holding the 2022 annual general meeting of shareholders.
2、 Opinions of the board of directors
The board of Directors believes that the company’s operation and management, financial status and solvency are good, and the total amount of loans and other legal debt financing from banks and other financial institutions is no more than 500 million yuan. The financial risk of financing is within the controllable range, which is in line with the relevant documents of China Securities Regulatory Commission and Shenzhen Stock Exchange and the articles of association, Help to promote the development of the company and business expansion.
According to the relevant provisions of the Shenzhen Stock Exchange GEM Listing Rules and the articles of association, the matters related to this proposal belong to the approval authority of the board of directors and do not need to be submitted to the general meeting of shareholders for deliberation.
3、 Opinions of the board of supervisors
The board of supervisors believes that the total amount of debt financing of the company and its subsidiaries by applying for loans from banks and other financial institutions and other legal means in 2022 is no more than 500 million yuan, which is conducive to accelerating the company’s capital turnover, improving the efficiency of capital use, meeting the actual needs of the company’s business development, and will not bring significant financial risks to the company and damage the interests of the company, There are no circumstances that harm the interests of investors. The board of supervisors approved the proposal of the company’s 2022 financing plan.
4、 Opinions of independent directors
In 2022, the company and its subsidiaries intend to apply for loans from banks and other financial institutions and other legal ways of debt financing with a total amount of no more than 500 million yuan, which is conducive to accelerating the company’s capital turnover and improving the efficiency of capital use, without damaging the interests of the company and shareholders. Moreover, the company is in good operating condition and has good solvency, which will not bring significant financial risks to the company and damage the interests of the company, and complies with the provisions of relevant laws and regulations such as the Listing Rules of gem shares of Shenzhen Stock Exchange. The independent directors agreed to matters related to this financing. 5、 Documents for future reference
1. Resolutions of the 17th meeting of the 4th board of directors of the company;
2. Resolutions of the 16th meeting of the 4th board of supervisors of the company;
3. Independent opinions of independent directors on matters related to the 17th meeting of the Fourth Board of directors of the company.
It is hereby announced
Jiangxi Sanxin Medtec Co.Ltd(300453) board of directors
March 17, 2022
